CHARLES SCHWAB INVESTMENT MANAGEMENT INC
Position in AKTS — Aktis Oncology, Inc.
CIK 884546
SAN FRANCISCO, CA
Position in AKTS
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$2,898,484
New position
Shares Held
162,017
first reported quarter
Ownership
0.293%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Mar 31, 2026CHARLES SCHWAB INVESTMENT MANAGEMENT INC holds $6,182,986,350 across 288 Biotechnology names. AKTS ranks #158 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
1,920,871 | $857,745,736 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
804,508 | $621,595,061 | |
| 3 | MRNA |
Moderna, Inc.
|
4,734,356 | $240,505,284 | |
| 4 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
673,356 | $222,793,299 | |
| 5 | INSM |
INSMED Inc
|
1,069,390 | $174,866,652 | |
| 6 | RVMD |
Revolution Medicines, Inc.
|
1,735,476 | $168,775,041 | |
| 7 | INCY |
Incyte Corp
|
1,729,102 | $162,743,080 | |
| 8 | BBIO |
BridgeBio Pharma, Inc.
|
1,976,094 | $146,744,740 |
All Filings in AKTS
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2,898,484 | 162,017 | Shares | Sole | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||